{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-076857","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2026-06-23T21:02:45+00:00","discovered_at":"2026-06-23T21:04:00.290589+00:00","generated_at":"2026-06-23T21:04:26.409145+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Theravance Biopharma SVP Áine Miller to depart Nov 15, 2026 as part of restructuring","bullets":["Dr. Miller, SVP Development and Head of Ireland Office, will terminate on Nov 15, 2026.","Termination is part of the restructuring announced by the Company in March 2026.","Company will make a special pension contribution of $250,000 within 30 days of termination.","Dr. Miller received a grant of 18,750 RSUs for continued service through the Termination Date.","Compromise agreement and side letter entered into on June 19, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-076857","json":"https://secwatch.observer/filing/0001104659-26-076857.json","markdown":"https://secwatch.observer/filing/0001104659-26-076857.md","text":"https://secwatch.observer/filing/0001104659-26-076857.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926076857/0001104659-26-076857-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926076857/tm2618538d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T21:04:26.409145+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}